Polycythemia Vera is a rare disorder marked by a continuous rise in the number of red blood cells in the blood, with an ...

Polycythemia vera (PV) is a blood cancer that begins in the marrow of your bones, the soft center where new blood cells grow. It causes your marrow to make too many red blood cells so your blood ...

The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...

The search for a partner for zerlasiran is ongoing, according to Silence. In the meantime, the biotech will focus its ...

Kind Pharmaceuticals LLC has patented substituted benzocyclobutene compounds acting as erythropoietin (EPO) production inhibitors reported to be useful for the treatment of cancer and polycythemia.

SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, ...

When Silence Therapeutics unveiled its latest zerlasiran phase 2 data at the American Heart Association (AHA) conference in ...

Presentation of full results from Phase 2 AURORA and BEACON studies at 2024 ASH Annual Meeting demonstrating significant ...

Kind Pharmaceuticals LLC has divulged erythropoietin (EPO) production inhibitors reported to be useful for the treatment of cancer and polycythemia.

H.C. Wainwright analyst Douglas Tsao raised the firm’s price target on Protagonist Therapeutics (PTGX) to $54 from $50 and keeps a Buy rating ...

Hypogonadism is a syndrome that affects both males and females. It’s associated with hormone deficiencies in the gonads ...